Research into non‐small cell lung cancer (NSCLC) has resulted in the development of several molecular therapeutic agents that target driver mutations, such as those in epidermal growth factor receptor (EGFR),4, 5, 6 anaplastic lymphoma kinase (ALK),7, 8ROS1,9, 10 and BRAF. 11These have a greater tumor‐shrinking effect and lower toxicity and confer longer progression‐free survival (PFS) than conventional cytotoxic drugs. This evidence concerns the gene ALK and neoplasm.